Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1

Details werden geladen...

https://www.manilatimes.net/2026/05/06/tmt-newswire/pr-newswire/norgine-welcomes-tga-registration-in-australia-of-pedmarqsi-sodium-thiosulfate-anhydrous-for-the-prevention-of-cisplatin-induced-hearing-loss-in-children1/2336660

Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1 | The Manila Times

**media[1044216]**PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to TGA registration provides an approved treatment option in an area of significant unmet medical need for children receiving cisplatin chemotherapyAMSTERDAM, May 6, 2026 /PRNewswire/ -- Norgine, a leading European specialty pharmaceutical company is pleased to announce that PEDMARQSI® (sodium thiosulfate anhydrous) has been registered by the Australian Therapeutic Goods Administration (TGA) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to

Norgine announces Swissmedic approval of PEDMARQSI for the prevention of cisplatin induced hearing loss in children

https://www.finanznachrichten.de/nachrichten-2026-03/68042041-norgine-announces-swissmedic-approval-of-pedmarqsi-for-the-prevention-of-cisplatin-induced-hearing-loss-in-children-008.htm

$https://www.manilatimes.net/2026/04/23/tmt-newswire/pr-newswire/minjuvi-tafasitamab-for-relapsed-or-refractory-follicular-lymphoma-approved-in-australia/2326771$

MINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in Australia | The Manila Times

https://www.manilatimes.net/2026/04/23/tmt-newswire/pr-newswire/minjuvi-tafasitamab-for-relapsed-or-refractory-follicular-lymphoma-approved-in-australia/2326771

FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program | The Manila Times

https://www.manilatimes.net/2026/04/24/tmt-newswire/globenewswire/fda-approves-first-ever-gene-therapy-for-treatment-of-genetic-hearing-loss-under-national-priority-voucher-program/2327730

OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients | The Manila Times

https://www.manilatimes.net/2026/04/27/tmt-newswire/globenewswire/ose-immunotherapeutics-welcomes-fda-orphan-drug-designation-granted-to-pegrizeprument-vel-101-for-prevention-of-organ-rejection-in-heart-transplant-patients/2328969

Nxera Pharma’s QUVIVIQ® (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia | The Manila Times

https://www.manilatimes.net/2026/04/14/tmt-newswire/globenewswire/nxera-pharmas-quviviq-daridorexant-25mg-and-50mg-receives-approval-in-taiwan-for-the-treatment-of-insomnia/2319716

$https://www.manilatimes.net/2026/03/02/tmt-newswire/pr-newswire/jaypirca-pirtobrutinib-approved-in-china-for-the-treatment-of-relapsed-or-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma/2290745$

Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | The Manila Times

https://www.manilatimes.net/2026/03/02/tmt-newswire/pr-newswire/jaypirca-pirtobrutinib-approved-in-china-for-the-treatment-of-relapsed-or-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma/2290745